← SynDRA
SOLCITINIB
SynDRA canonical compound SYN0038036 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | JAK1 |
|---|
| Mechanism of action | JAK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- JAK1 INHIBITOR
- Tyrosine-protein kinase JAK1 inhibitor
- JAK2 INHIBITOR
- JAK3 INHIBITOR
- TYK2 INHIBITOR
- JAK inhibitor
- JAK1 MODULATOR
Cross-references
Synonyms
- GLPG-0778
- GSK-2586184
- G-154578
- G154578
- GLPG-0788
- GLPG0778
- GSK-2586184A
- GSK2586184A
- GSK2586184
- GLPG 0778
- GSK 2586184
- 3V7GQ1260K
- solcitinibum
- RefChem:1098881
- MFCD26960569
- Solcitinib [USAN:INN]
- UNII-3V7GQ1260K
- Solcitinib [USAN]
- SolcitinibGLPG0778
- SolcitinibGLPG0778?
- SOLCITINIB [INN]
- Solcitinib (USAN/INN)
- SOLCITINIB [WHO-DD]
- GTPL9697
- orb1303990
- SCHEMBL2240393
- MPYACSQFXVMWNO-UHFFFAOYSA-N
- BDBM128101
- GLXC-90515
- EX-A2326
- GYB16345
- s5917
- AKOS025289798
- compound 1 [WO2010149771]
- CS-5204
- SB16965
- NCGC00484062-01
- AC-30938
- AS-56075
Look up SOLCITINIB in the interactive SynDRA portal →